PRECIGEN, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
PRECIGEN, INC. (PGEN) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $127.50 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2019-11-12
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-09-30 was $37.50M, a 150.42% increase year-over-year.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-06-30 was $45.00M.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-03-31 was $45.00M, a 650.00% increase year-over-year.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-12-31 was $45.00M, a 17.67% increase year-over-year.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2018 was $65.97M, a 62.20% decline from fiscal 2017.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $174.54M, a 71.14% increase from fiscal 2016.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $101.99M, a 15.89% increase from fiscal 2015.
- PRECIGEN, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2015 was $88.00M, a 28.45% decline from fiscal 2014.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-09-30 | $37.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $82.50M derived: sum of 2 quarters · filed 2019-11-12 | $127.50M 10-Q · filed 2019-11-12 | $172.50M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $90.00M 10-Q · filed 2019-08-09 | $135.00M derived: sum of 3 quarters · filed 2019-08-09 | $149.97M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-03-31 | $45.00M 10-Q · filed 2019-05-09 | $90.00M derived: sum of 2 quarters · filed 2019-05-09 | $104.97M derived: sum of 3 quarters · filed 2019-11-12 | $104.97M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-12-31 | $45.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $59.98M derived: sum of 2 quarters · filed 2019-11-12 | $59.98M derived: sum of 3 quarters · filed 2019-11-12 | $65.97M 10-K · filed 2019-03-01 |
| 2018-09-30 | $14.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $14.97M derived: sum of 2 quarters · filed 2019-11-12 | $20.98M 10-Q · filed 2019-11-12 | $59.22M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $6.00M 10-Q · filed 2019-08-09 | $44.24M derived: sum of 3 quarters · filed 2019-08-09 | $92.54M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $6.00M 10-Q · filed 2019-05-09 | $44.24M derived: sum of 2 quarters · filed 2019-05-09 | $92.54M derived: sum of 3 quarters · filed 2019-05-09 | $135.54M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $38.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $86.54M derived: sum of 2 quarters · filed 2019-03-01 | $129.54M derived: sum of 3 quarters · filed 2019-03-01 | $174.54M 10-K · filed 2019-03-01 |
| 2017-09-30 | $48.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $91.30M derived: sum of 2 quarters · filed 2018-11-08 | $136.30M 10-Q · filed 2018-11-08 | $166.30M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $43.00M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13 | $88.00M 10-Q · filed 2018-08-13 | $118.00M derived: sum of 3 quarters · filed 2019-03-01 | $148.00M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $45.00M 10-Q/A · filed 2018-08-13 | $75.00M derived: sum of 2 quarters · filed 2019-03-01 | $105.00M derived: sum of 3 quarters · filed 2019-03-01 | $128.99M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $60.00M derived: sum of 2 quarters · filed 2019-03-01 | $83.99M derived: sum of 3 quarters · filed 2019-03-01 | $101.99M 10-K · filed 2019-03-01 |
| 2016-09-30 | $30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $53.99M derived: sum of 2 quarters · filed 2017-11-09 | $71.99M 10-Q · filed 2017-11-09 | $89.99M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $23.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $41.99M 10-Q · filed 2017-08-09 | $59.99M derived: sum of 3 quarters · filed 2018-03-01 | $81.99M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $18.00M 10-Q · filed 2017-05-10 | $36.00M derived: sum of 2 quarters · filed 2018-03-01 | $58.00M derived: sum of 3 quarters · filed 2018-03-01 | $82.00M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $40.00M derived: sum of 2 quarters · filed 2018-03-01 | $64.00M derived: sum of 3 quarters · filed 2018-03-01 | $88.00M 10-K · filed 2018-03-01 |
| 2015-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $46.00M derived: sum of 2 quarters · filed 2016-11-09 | $70.00M 10-Q · filed 2016-11-09 | $94.75M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $48.00M 10-Q · filed 2016-08-09 | $72.75M derived: sum of 3 quarters · filed 2017-03-01 | $97.25M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $24.00M 10-Q · filed 2016-05-10 | $48.75M derived: sum of 2 quarters · filed 2017-03-01 | $73.25M derived: sum of 3 quarters · filed 2017-03-01 | $111.74M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $24.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $49.24M derived: sum of 2 quarters · filed 2017-03-01 | $87.74M derived: sum of 3 quarters · filed 2017-03-01 | $122.99M 10-K · filed 2017-03-01 |
| 2014-09-30 | $24.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $63.00M derived: sum of 2 quarters · filed 2015-11-09 | $98.25M 10-Q · filed 2015-11-09 | $127.74M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $38.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $73.75M 10-Q · filed 2015-08-10 | $103.25M derived: sum of 3 quarters · filed 2016-02-29 | |
| 2014-03-31 | $35.25M 10-Q · filed 2015-05-11 | $64.75M derived: sum of 2 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $29.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $45.00M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $15.50M 10-Q · filed 2014-11-13 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |